PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated lymphoma patients.

Anthracycline-mediated cardiotoxicity is a common concern following lymphoma therapy, particularly in patients with high cardiovascular risk (CVR). In non-cancer populations, coronary artery calcium scoring (CACS) effectively identifies individuals who may benefit from aggressive CVR modification to lower the risk of cardiovascular events. Emerging evidence suggests that CACS can also predict cancer therapy-related cardiotoxicity, potentially identifying candidates for cardioprotective strategies.